Avistone Biotechnology at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

Avistone Biotechnology brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on brain-penetrant kinase inhibitors with broad preclinical activity. They introduce ANS05, an irreversible HER2 TKI aimed at clinically relevant HER2 alterations, and ANS02, a non-covalent EGFR TKI that overcomes resistance mutations in EGFR-mutant NSCLC models.

Organization	ENA 2026 Attendance
Avistone Biotechnology Beijing, China
avistonebio.com Biotech Commercial-stage oncology company with the MET inhibitor vebreltinib marketed in China and brain-penetrant EGFR and HER2 inhibitors in development.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ANS05, a Novel Irreversible Brain-penetrant HER2 TKI, Targets Clinically Relevant HER2 Alterations and Demonstrates Potent Broad-Spectrum Preclinical Activity Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ANS02, a Novel, Non-covalent, Brain-penetrant EGFR TKI, Overcomes Clinically Relevant Resistance Mutations and Demonstrates Broad Preclinical Activity in EGFR-Mutant NSCLC Models Targeted agents

Organization

ENA 2026 Attendance

Avistone Biotechnology

Beijing, China

avistonebio.com

Biotech

Commercial-stage oncology company with the MET inhibitor vebreltinib marketed in China and brain-penetrant EGFR and HER2 inhibitors in development.

Poster

Thu Nov 19
9:30–10am
1–3pm
4:30–5pm

Part of Poster session: Molecular Targeted Agents

ANS05, a Novel Irreversible Brain-penetrant HER2 TKI, Targets Clinically Relevant HER2 Alterations and Demonstrates Potent Broad-Spectrum Preclinical Activity

Targeted agents